Topic Listing for Abraxis BioScience

Abraxane Clinical Development Label Expansion Global Commercialization Plans Abraxane Clinical Trial Update
Abraxane Co-promotion Abraxane Market Data Highlights
Abraxane Proprietary Injectable Oncology Product Abraxane Revenue
Abraxane Revenue Recognition Abraxane Size1 Co-promotion
Abraxane Size1 Revenue Abraxane Size1 Revenue Recognition
Abraxis Appeal Jury Ruling Elan Patent Infringement Claim Abraxis Bioscience
Abraxis Bioscience Inc Abraxis Translational Molecular Bioscience Cnsi
Acceptance Gifts Entertainment Loans Other Favors Access Information
Accounts Receivable Concentration Credit Risk Accrued Liabilities
Accumulated Other Comprehensive Loss Accuracy Reports Records Accounts
Acquired In-process Research Development Acquires Prometic Shares
Acquisition Acquisition App
Acquisition Assets Acquisition Manufacturing Facility Phoenix Arizona
Acquisition Other Transactions Acquisition Puerto Rico Manufacturing Facility
Acquisition Shimoda Biotech Platco Technologies Acquisitions
Acquisitions Other Transactions Action Without Meeting
Actions Taken Chief Executive Officer Entities Affiliated Him Actions Taken Chief Executive Officer His Wife Entities
Addition Information Contained Elsewhere Statement Consider Carefully Following Administrative Complaints Litigation
After Separation Distribution Agreements Neos
Agreements Related Separation Aircraft Purchase Sale Agreement
Allocated Expenses Allocation Employment Alpha Employees Generico
Amendments Amortization 2006 Merger Costs
Amortization 2006 Merger Related Costs Other Amortization Acquired Intangible Assets
Amortization Intangible Assets Annual Meetings
Anti-boycott Compliance Anti-kickback Statute
Anti-takeover Provisions Approvals Waivers
Arbitration Assets Liabilities Measured Fair Value Nonrecurring Basis
Assumption Employee Related Obligations Assumption Non-erisa Benefit Arrangements Generico Group Cessation Participation
Assumption Welfare Plans Generico Group Cessation Participation Astrazeneca Limited
Audit Related Fees Authority Advance Expenses
Authority Insure Authority Purpose
Available Information Available Sale Securities
Available-for-sale Securities Background
Basis Accounting Combination Basis Consolidation
Basis Consolidation Combination Basis Presentation
Batch Cost Pipeline Product Because Not Been Public Market Common Stock Price
Become Subject Federal False Claims Other Similar Litigation Become Subject Federal State False Claims Other Similar
Been Operating Loss Beneficial Ownership Reporting Compliance
Biocon Agreements Biocon Limited
Biomarkers Molecular Profiling Biosimilars
Bonus Cash Incentive Plans Bribery Corruption
Business Business Relationships
California Nanosystems Institute Cancer Drug Discovery Targeting Tumor Suppressor P53
Capital Requirements Capitalization
Carlo Montagner Cash Collateral Reacquisition Agreement
Cash Contribution Cash Equivalents
Cash Equivalents Short-term Investments Cenomed Biosciences Llc
Cenomed Joint Venture Central Nervous System Therapies
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certification Changes Internal Controls
Chargebacks Chicago Bioscience Mortgage
Chief Executive Officer Entities Affiliated Him Collectively Own Clinical Commercial Validation Nab Tumor Targeting Technology
Clinical Trial Accounting Clinical Trial Agreements
Clinical Trial Other Commitments Code Business Conduct
Code Ethics Collaborative Agreements Other Licensing Obligations
Commitment Committee Structure Membership
Committees Common Stock
Compensation Committee Compensation Committee Board Directors
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Directors Compensation Discussion Analysis
Compensation Philosophy Competition
Compliance Compliance Reporting
Comprehensive Income Comprehensive Loss
Comprehensive Loss Income Conference Call Information
Confidential Information Conflicts Interest
Consent Independent Registered Public Accounting Firm Contingencies
Contractual Allowances Returns Credits Bad Debts Contractual Allowances Returns Credits Cash Discounts Bad Debts
Contractual Obligations Contractual Obligations Off-balance Sheet Arrangements
Controlled Status Director Independence Controls Procedures
Converted Stock-based Compensation Plans Cooperation
Corporate Information Credit Facility
Critical Accounting Policies Estimates Cyclodextrin-based Delivery Technology
David Otoole Edward Geehr Deferred Financing Costs
Defined Contribution Plans Definitions
Depend Heavily Principal Members Management Research Development Teams Depend Parties Supply Raw Materials Other Components Not
Dependent App Manufacture Abraxane Remaining Term Pharmaceutical Products Dependent App Manufacture Abraxane Term Pharmaceutical Products Highly
Dependent New App Llc Manufacture Abraxane Term Pharmaceutical Dependent New App Manufacture Abraxane Term Pharmaceutical Products
Description Business Director Nominations
Directors Executive Officers Directors Executive Officers Corporate Governance
Disputes Distribution
Distribution Conditions Termination Distribution Taxable New App Abraxis Acquisition Outstanding Common
Dividend Policy Documents Incorporated Reference
Drug Discovery Strategies Dual Officer Agreement
Duplication Payments Earnings Per Share Information
Effect Amendment Effect Certain Sales Acquisitions Stock New Abraxis App
Election Directors Elements Executive Compensation
Employee Benefit Plan Employee Benefit Plans
Employee Information Confidentiality Employee Matters Agreement
Employee Stock Purchase Plan Employees
Employment Agreement Carlo Montagner Employment Agreement Lisa Gopala
Employment Agreement Lisa Gopalakrishnan Gopala Employment Agreements
Employment Agreements David Otoole Edward Geehr Environment
Environmental Equity Compensation Plan Information
Equity Compensation Plans Equity Income Drug Source Llc
Equity Net Income Unconsolidated Entities Equity-based Compensation
Estimates Evaluation Disclosure Controls Procedures
Exact Name Registrant Specified Charter Except Per Share Amounts
Exclusive License Intellectual Property Portfolio Execution Corporate Instruments
Executive Chairman Entities Affiliated Him Collectively Own Significant Executive Compensation
Executive Sessions Non-management Directors Exhibits
Expense Recognition Explanatory
Face Uncertainty Related Pricing Reimbursement Health Care Reform Facilitating Payments Low-level Non-us Governmental Employees Officials Non-discretionary
Fair Value Fair Value Financial Instruments
Fair Value Measurement Fair Value Other Financial Instruments
Fda Federal Bankruptcy Laws Comparable Provisions State Fraudulent Transfer
Fees Compensation Financial Instruments
Financial Results 2008 2007 Financial Results 2009
Financial Statement Schedule Financial Statements
Financial Statements Exhibits Financing Activities
Fixing Record Dates Following Date Such Termination Continuous Service Qualifying Retirement
Force Majeure Service Interruption Restoration Foreign Currency Translation
Foreign Plans Form 10-k
Form 10-k Annual Report Form 10-q
Form Execution Certificates Former Name Address Changed Since Last Report
Forward-looking Statement Forward-looking Statements
Full-year 2008 Financial Results Funds Property
General General Information
General Provisions Generico Insurance
Gifts Entertainment Global Approval Status Abraxane
Global Development Team Goodwill Intangible Assets
Government Inquiries Investigations Grantee Acknowledges Agrees
Grants Plan-based Awards Table Green Cross Corporation
Gross Profit Harassment-free Workplace
Healthcare Laws Healthcare Regulatory Compliance
Highlights Highly Dependent Strong Market Acceptance Abraxane
Historical Financial Information Not Representative Future Results Independent Historical Pro Forma Financial Information Not Representative Future
History Operating Independent Unable Make Changes Necessary Operate Holding Merger
Holding Merger Separation Distribution Identified Intangible Assets
Immunotherapeutics Related Assay Systems Impact Regulatory Requirements Compensation
Impairment Charge Impairment Long-lived Assets
Import Export Regulation Trade Compliance In-process Research Development
Inability Protect Intellectual Property Rights United States Foreign Income Taxes
Independent Registered Public Accounting Firm Index
Index Exhibits Index Inancial Statements
Information Reporting Backup Withholding Injectable Pharmaceutical Products Markets Highly Competitive Unable Compete
Insider Trading Insider Trading Communications Parties
Insider Trading Policy Intangible Assets
Intangible Assets Other Non-current Intellectual Property
Internet Availability Proxy Materials Inventories
Investing Activities Investment Drug Source Llc
Investment License Agreements Prometic Life Sciences Inc Investments
Investments Expression Pathology Investments Unconsolidated Entities
Investors Media Inquiries Issuer Purchases Equity Securities
Johns Health Center Key Transactions
Kickbacks Lease Agreement
Leases Leases Commitments
Legal Proceedings Limitation Liability Indemnification Directors Officers
Limited History Operating Independent Unable Make Changes Necessary Lisa Gopala
List Stockholders List Subsidiaries
Litigation Litigation Costs
Loss Assets Revenue Cash Flows Results Operations Abraxis Loss Operating Diversification Adversely Affect Financial Position Operations
Lost Certificates Management
Managements Report Internal Control Over Financial Reporting Manner Effecting Separation Distribution
Manufacturing Manufacturing Agreement
Market Common Stock Market Registrants Common Equity Related Stockholder Matters Issuer
Marketable Securities Marketing Integrity
Material Federal Income Tax Consequences Material Information
Meetings Meetings Attendance
Merger Merger Amortization 2006 Costs
Merger Goodwill Intangibles Merger Related Costs
Minutes Miscellaneous
Mutual Respect Teamwork Valuing Differences Nab Pipeline
Nab Tumor Targeting Technology Platform Natural Product Drug Discovery Platform
Need Change Business Practices Comply Changes Subject Charges Net Revenue
New Abraxis Inc New Alpha Insurance
Nominations Persons Election Board Directors Nominees Directors
Non-employee Director Stock Option Program Non-gaap Financial Measures
Non-public Information Not Subject Provisions 203 Delaware General Corporation Law
Notes Pro Forma Combined Financial Statements Notice 2008 Annual Meeting Stockholders
Notice 2009 Annual Meeting Stockholders Notice Meetings
Notice Restricted Stock Bonus Award Notice Restricted Stock Unit Award
Notice Stock Option Award Notices
Nucleic Acid Complementation Technology Number 001-33657
Number Term Office Off-balance Sheet Arrangements
Officers Designated Open Door Policy
Operating Activities Operating Results
Option Exercises Stock Vested Other
Other Agreements Other Companies Claim Infringe Intellectual Property Proprietary Rights
Other Deferred Revenue Other Executive Benefits Perquisites
Other Income Other Matters
Other Non-operating Other Offices
Other Revenue Other Securities Corporation
Other Services Outside Employment
Overcoming Obstacles Toxicity Solvents Overview
Par Value 0001 Per Share Part
Part Other Information Patient Privacy
Payment Services Payments Termination
Per Share Information Person Means Individual Corporation Limited Liability Partnership Association
Personal Investments Transactions Personal Relationships
Personnel Records Phase Clinical Trials
Place Meetings Plan
Please Detach Mail Envelope Provided Please See Separation Distribution Detailed Description Matters Summarized
Please Sign Date Return Proxy Card Promptly Using Pluripotent Adult Stem Cells
Policy Statement Post-termination Compensation
Potential Conflicts Interest App Potential Conflicts Interest New App
Power Attorney Powers
Pre-distribution Transactions Preferred Stock
Principal Accountant Fees Services Pro Forma Combined Financial Statements
Product Experience Prometic Life Sciences Inc
Properties Property Plant Equipment
Property Purchase Proposed 2009 Spin-off
Proposed 2010 Spin-off Proposed Spin-off
Proprietary Product Development Efforts Not Result Commercial Products Provision Income Taxes
Provisions Nonexclusive Purchase Obligations
Pursuant Requirements Securities Exchange Act 1934 Registrant Duly Pursuant Requirements Securities Exchange Act 1934 Report Been
Quantitative Qualitative Disclosures Market Risk Quarterly Financial Data
Quarterly Period 2008 Quarterly Period 2009
Questions Answers Separation Distribution Quorum Voting
Raw Materials Reacquisition Costs
Real Estate Leases Reason Furnishing Information Statement
Reasons Separation Distribution Rebates
Rebates Returns Credits Recent Accounting Pronouncements
Recent Developments Recent Highlights
Recital Recitals
Reclassification Reclassifications
Regarding Forward-looking Statements Registered Office
Registered Stockholders Registration Rights
Registration Rights Agreement Registration Rights Agreement Signature Page
Registration Statement Means Form Initially Filed New Alpha Regulatory Considerations
Regulatory Matters Related Party Transactions
Relationships Among Directors Executive Officers Release
Report Audit Committee Report Independent Registered Public Accounting Firm
Reporting Procedures Other Inquiries Required Defend Lawsuits Pay Damages Product Liability Claims
Required Indemnify App Not Able Collect Indemnification Rights Required Indemnify New App Not Able Collect Indemnification
Required Perform Additional Clinical Trials Change Labeling Products Research Development
Research Development Costs Research Development Highlights
Research Revenue Recognition Resignations Removals
Restricted Stock Restricted Stock Bonus Award Agreement
Restricted Stock Units Restricted Unit Plan
Restricted Unit Plans Results
Results Operations Results Operations Financial Condition
Results Separation Distribution Retention Records Access
Returns Credits Cash Discounts Bad Debts Revenue Recognition
Revocability Proxies Right Claimant Bring Suit
Right Indemnification Risk Factors
Risks Related Investment Common Stock Risks Relating Separation Old Abraxis
Sale Assets Sales Marketing
Sales Provisions Schedules
Securities Authorized Issuance Equity Compensation Plans Securities Exchange Act 1934
Securities Registered Pursuant Act Security Ownership Certain Beneficial Owners Management Related Stockholder
See Accompanying Notes Combined Financial Statements See Accompanying Notes Condensed Combined Financial Statements
See Accompanying Notes Consolidated Combined Financial Statements Segment Information
Select Clinical Product Candidates Selling General Administrative
Selling General Administrative Sga Senior Management
Separation Separation Abraxis Bioscience
Separation Abraxis Bioscience Present Significant Challenges Separation Old Abraxis Present Significant Challenges
Services Settlement Claims
Severance Obligations Shares Subject Option Shall Vest After Vesting Commencement
Shipping Handling Fees Costs Signature
Signature Page Follows Signatures
Solicitation Voting Procedures Sources Financing
Sources Financing Capital Requirements Sources Uses Cash
Sparc Special Forward-looking Statements
Special Meetings Specialised Therapeutics Australia Pty Ltd
State Pharmaceutical Marketing Compliance Reporting Requirements Expose Regulatory Statement Policy
Stock Assignment Separate Certificate Stock Compensation
Stock Incentive Plan Stock Option Plan
Stock Performance Graph Stock Price Volatile Response Market Other Factors
Stock Repurchase Program Stock-based Compensation
Stock-based Compensations Stockholder Communications Board Directors
Stockholder Proposals Stockholder Proposals Annual Meetings
Stockholders Equity Strategic Relationships
Strategy Strategy License Rights Acquire Commercialize Proprietary Biological Injectable
Structure Meetings Subject Risks Associated International Operations Harm Domestic
Submission Matters Vote Security Holders Subrogation
Subsequent Event Subsequent Events
Substance-free Workplace Substantial Sales Common Stock Depress Market Price
Substantial Sales Common Stock Following Separation Distribution Depress Successful Attract Retain Motivate Key Employees Inability Seriously
Summary Summary Significant Accounting Policies
Supplemental Disclosure Cash Flow Information Suppliers Unable Comply Ongoing Changing Regulatory Standards Sales
Survival Liabilities Survival Rights
Table Contents Taiho Pharmaceutical Ltd
Tax Allocation Agreement Tax Audits
Tenure Duties Officers Termination
Termination Agreement Territories
Trading Transactions App Pharmaceuticals
Transactions App Pharmaceuticals Inc Transfer Agent Registrar
Transfers Transition Services Agreement
Translational Molecular Bioscience Cnsi Treasury Stock
Treatment Employee Stock Options Restricted Units Unable Integrate Successfully Potential Future Acquisitions Business Harmed
Unit Cost Abraxane United States
Universal Shelf Registration Statement University Southern California
Upcoming Scientific Congresses Uses Sources Cash
Vacancies Various Other 2008 Agreements
Vesting Schedule Voting Procedures Inspectors Elections
Voting Rights Voting Securities Owned Corporation
Warranties Liabilities Welfare Plan Liabilities
Work Environment Workplace Safety
Xvi Xvii
Xviii Year-to-date 2008 Financial Results
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki